RHEB and cancer: Similar to the engineered Y35A and Y35F mutations, we found that the cancer-associated Y35N RHEB mutation increased the rate of intrinsic GTP hydrolysis by ~2.5 fold, due to release of the autoinhibitory function of Y35.